NR

NR

NR (nicotinamide riboside) is a precursor your body uses to make NAD+, the central coenzyme that powers cellular energy production, DNA repair, and the activity of the sirtuin enzymes that regulate aging. NAD+ levels in skin, blood, muscle, and brain drop substantially as you age, and NR is one of the two main supplements people use to top them back up (the other is NMN).
Most people take it as a daily anti-aging supplement, with the strongest case being for older adults, women going through perimenopause and beyond, and anyone with metabolic or cardiovascular issues. Compared to NMN, NR has more years of human trials behind it, cleaner pharmacokinetic data, and a clearer regulatory path. The clearest human signals so far are reductions in systolic blood pressure and arterial stiffness in older adults with elevated BP, increased brain NAD+ in Parkinson's patients with mild clinical improvement, and reductions in inflammatory markers. If you're under 40 and metabolically healthy, the expected functional benefit is smaller and the case rests more on long-term prevention than anything you'll feel.

Deep-dive

NAD+ is required for hundreds of enzymatic reactions, but the ones that matter most for aging are the sirtuins (SIRT1-7) and PARPs. Sirtuins are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, fat metabolism, inflammation, and DNA repair. PARPs use NAD+ to repair single-strand DNA breaks. Both compete for the same NAD+ pool, and as DNA damage accumulates with age, PARPs consume more NAD+, leaving less for sirtuins. The result is the broad metabolic and inflammatory drift we see in older tissue.
NR sits two steps upstream of NAD+. It's converted first to NMN by NRK1 or NRK2, then to NAD+ by NMNAT. Crucially, NRK2 is upregulated in tissues under stress (injured neurons, muscle under load, stressed cardiac tissue), which is part of why NR seems to work best in compromised populations rather than in healthy young people. Where the substrate is most needed, the conversion machinery is most active.
Bioavailability is one of NR's clearer advantages. The first human pharmacokinetic trial in 2016 showed that single oral doses of 100, 300, and 1000 mg produced dose-dependent rises in blood NAD+ within hours, with a 2.7-fold increase at the high dose. Subsequent work has shown NR raises NAD+ in whole blood, peripheral immune cells, urine, muscle, and (importantly) brain. NR appears to enter cells through dedicated nucleoside transporters that NMN lacks, which is part of the case for it being more directly bioavailable, though some of the orally administered NR also gets broken down in the gut and reassembled in the liver via the salvage pathway, so the picture isn't as clean as it once looked.
Brain penetration is the strongest mechanistic distinction from NMN. The NADPARK phase I trial in newly diagnosed Parkinson's patients gave 1000 mg/day NR or placebo for 30 days. NR significantly raised cerebral NAD+ levels measured directly by 31P magnetic resonance spectroscopy, raised CSF NAD+ metabolites, and produced mild clinical improvement in those who were responders. It also reduced inflammatory cytokines in serum and CSF. The follow-up NR-SAFE trial escalated to 3000 mg/day for 30 days and found it safe and well tolerated with no methyl donor depletion, opening the door for higher-dose neurodegenerative trials. Whether this translates into actually slowing Parkinson's progression is being tested in the ongoing 400-person NOPARK phase II trial. NMN doesn't have comparable cerebral NAD+ data in humans.
Cardiovascular function in older adults. This is where the strongest healthy-population signal sits. The Martens 2018 trial gave 500 mg twice daily NR or placebo for 6 weeks to 30 healthy middle-aged and older adults. It safely doubled NAD+ levels and produced a modest reduction in systolic blood pressure, with the effect concentrated in those who started with elevated BP (a 9 mmHg reduction in that subgroup). The follow-up 3-month trial in 52 midlife and older adults with above-normal SBP confirmed reductions in systolic blood pressure and improved vascular endothelial function. This is one of the cleaner outcome signals across the entire NAD+ precursor literature.
Heart failure. A 2022 trial in 30 patients with heart failure with reduced ejection fraction gave 1000 mg twice daily for 12 weeks. NR was safe and roughly doubled blood NAD+. The NAD+ rise correlated with increased mitochondrial respiration in immune cells and reduced expression of NLRP3, a key inflammasome involved in cardiac inflammation. The trial wasn't powered to show clinical improvement, but the mechanistic signal was there.
Muscle and metabolic outcomes are the weak spot. A 5-month twin study escalating NR from 250 to 1000 mg/day in BMI-discordant twin pairs improved muscle mitochondrial number, satellite cell differentiation, and gut microbiota composition, but did not improve adiposity, insulin sensitivity, or any clinical metabolic marker. Most short-term NR trials in healthy overweight adults have similarly failed to show meaningful changes in body composition, insulin sensitivity, or fat in the liver, despite reliably raising NAD+. This is a real gap from the mouse data and is one of the honest reasons to keep expectations modest. NMN has the cleaner muscle insulin sensitivity result (in postmenopausal women specifically); NR doesn't have an equivalent.
What it doesn't do, in humans. No human trial of NR has shown reversal of biological age, lifespan extension, hair pigmentation restoration, or anything resembling the dramatic anti-aging effects from mouse work. The mouse-to-human translation has been disappointing across the NAD+ precursor field, not just for NR. The realistic frame is: NR raises NAD+, may benefit cardiovascular function in older adults with elevated BP, may protect the brain in neurodegenerative contexts, and may modestly support mitochondrial function. Beyond that, the human evidence thins out fast.
Women. Multiple NR trials have included substantial proportions of women (the Martens cardiovascular trial was mostly postmenopausal women), and the cardiovascular benefits appear similar between sexes. There's no reason to expect different dosing for women. Premenopausal women have higher baseline NAD+ than men of similar age, partly because oestrogen upregulates NAMPT, the enzyme that makes NMN. So premenopausal women may have less room for NR to add on top, while perimenopausal and postmenopausal women, who lose this oestrogen-driven NAD+ support, are likely the strongest responders. Skip during pregnancy and breastfeeding, the safety data isn't there.
Older adults. This is the population with the most evidence and the largest expected benefit, since NAD+ has dropped furthest from baseline. The cardiovascular trials, the heart failure trial, and the Parkinson's trials have all been in this group. If you're young and healthy, your expected benefit is smaller and the case for daily lifelong supplementation rests on prevention rather than felt effect.
NR vs. NMN. Both feed the same NAD+ pool but enter the pathway at different points. NR has more total years of human trial data, cleaner pharmacokinetics, demonstrated cerebral NAD+ elevation, and the Niagen form has FDA NDI and GRAS notifications plus regulatory clearance in multiple countries. NMN has the muscle insulin sensitivity result in postmenopausal women and the older men muscle function trial. Functionally for most people, the two are close enough that practical factors (cost, availability, regulatory comfort) probably matter more than the molecular distinction. Don't stack them at high doses, you'd be paying twice to feed the same pool and increasing the methyl donor consumption load.

Dosage:

  • Standard daily dose: 300-1000 mg/day. 300 mg/day reliably raises blood NAD+ by roughly 50%, 1000 mg/day roughly doubles or triples it. The cardiovascular trials that showed BP reductions used 500 mg twice daily (1000 mg/day total). The Parkinson's trials used 1000 mg/day, with safety established up to 3000 mg/day
  • For general anti-aging in healthy adults: 300-500 mg/day is the practical and well-studied range
  • For elevated blood pressure or cardiovascular focus: 1000 mg/day is what worked in the trials, ideally split as 500 mg twice daily
  • For neurological or higher-need contexts: up to 1000 mg twice daily under medical supervision. Higher doses are tolerated but the marginal benefit is unclear
  • Timing: Take in the morning. NAD+ has a circadian rhythm, peaking in the morning, and supplementing aligns with that natural cycle. Some people report mild stimulation, so avoid late-day dosing
  • With or without food: Either works. NR absorption isn't strongly food-dependent. Take with food if you get mild GI upset
  • Forms: Niagen (NR chloride) is the patented form used in nearly every published clinical trial and is what to default to. It has the clearest manufacturing standards and the regulatory clearances. Generic NR exists but quality varies. Avoid mystery-source NR from cheap suppliers
  • Cycling: Not necessary. NR feeds a depleted substrate pool, it doesn't downregulate receptors with continuous use. Daily continuous use is the protocol that's been studied
  • Stacks: Some people pair with TMG (trimethylglycine) at 500-1000 mg/day on the theory that NAD+ metabolism consumes methyl groups via excreted methylated metabolites, which could in principle deplete methyl donors and raise homocysteine. The mechanistic concern is real but the high-dose NR-SAFE trial at 3000 mg/day for 30 days found no methyl donor depletion, so at typical doses TMG is probably unnecessary. If you're running 1000 mg+ chronically, adding TMG is cheap insurance. Pterostilbene is sometimes co-formulated (the Basis product), based on a 2017 trial showing combined supplementation raises NAD+ effectively, but the independent contribution of pterostilbene is not well established
  • Older vs. younger users: Older adults (50+), perimenopausal and postmenopausal women, and those with metabolic or cardiovascular dysfunction are the populations most likely to notice anything. If you're under 40 and metabolically healthy, the realistic expectation is no felt effect, and you're betting on long-term prevention

Here's what you can expect:

For most people, nothing acute. NR doesn't produce a noticeable effect the way caffeine, modafinil, or even creatine does. You won't feel sharper, more energetic, or younger after a single dose, or after a week.
What the evidence supports, with consistent daily use over 8-12+ weeks: in older adults with elevated systolic blood pressure, modest reductions in BP and improved vascular endothelial function. In Parkinson's patients (and likely in other neurodegenerative contexts), measurable increases in brain NAD+ with mild clinical improvement in responders. In adults with chronic inflammation, reductions in inflammatory cytokines. In younger, healthy adults, mostly an unfelt rise in blood NAD+ with uncertain functional payoff.
Don't expect the dramatic anti-aging effects you've seen claimed. Those come from mouse studies that haven't translated cleanly to humans. The realistic frame is that NR may slow some of the cellular drift that comes with aging, particularly in tissues that have lost the most NAD+, and may meaningfully help cardiovascular and neurological function in those who are already showing decline. The case is stronger the older you are.

Side effects & risks:

  • GI discomfort is the most common side effect. Nausea, bloating, mild stomach upset, especially at doses above 500 mg or on an empty stomach. Take with food if it bothers you
  • Headache, flushing, or feeling slightly stimulated can occur in some people, especially when starting. Usually transient. Unlike niacin, NR does not cause the classic flushing reaction. If you get persistent headaches, drop the dose
  • Sleep disruption if taken late in the day. Morning dosing is the simple fix
  • Methylation concerns at high chronic doses. NAD+ metabolism produces methylated nicotinamide metabolites that the body excretes, which uses up methyl groups. The theoretical concern is that high-dose chronic NR could raise homocysteine or deplete methyl donors. The NR-SAFE trial at 3000 mg/day for 30 days found no methyl donor depletion, so at typical doses (300-1000 mg/day) this is largely a non-issue. At sustained higher doses, TMG, choline, folate, and B12 all support methylation if you're concerned
  • Active cancer is the main caution. NAD+ is used by all cells, including cancer cells, for DNA repair and energy production. Cancers often upregulate NAMPT to feed their own NAD+ demand. The data on whether NR supplementation accelerates existing tumour growth is mixed and there are no human trials in cancer patients. If you have an active cancer diagnosis or are in remission from an aggressive cancer, avoid NR until you've discussed it with your oncologist
  • Pregnancy and breastfeeding: skip it. No safety data
  • Long-term safety data is limited. The longest controlled human trials have run 5-12 months. Beyond that, the data thins out. NR appears safe at typical doses based on what we have, but the multi-decade trajectory is unknown
  • Interactions with medications are not well studied. No significant ones have been flagged in the trial literature. Caution if you're on chemotherapy, immunosuppressants, or anything that affects NAD+ metabolism (most chemo agents do)
🩸

Blood markers

Blood pressure (resting systolic and diastolic), baseline before starting and at 3 months. NR's clearest functional benefit in human trials is in adults with elevated SBP, this is where you'd expect to see something move if it's working.
Lipid panel (LDL, HDL, triglycerides), baseline and at 3-6 months. Standard cardiovascular tracking.
hs-CRP and homocysteine, baseline and at 6 months if running higher chronic doses. Homocysteine is the methylation marker to watch, if it rises on NR, that's the signal to add a methyl donor like TMG.
Fasting glucose, fasting insulin, HbA1c, baseline and at 6 months. NR's metabolic effects in healthy adults are weaker than NMN's, but still worth tracking if you're using it for general anti-aging.
Liver enzymes (ALT, AST) and kidney function (creatinine, eGFR), baseline. No specific NR-related concerns documented but standard for any chronic supplementation.
Intracellular NAD+ (PBMC NAD+ assay) is the direct measurement of whether NR is doing what it's supposed to do. Not standard on most lab panels but available through specialty labs (Jinfiniti, Genova, etc.). Useful at baseline and 3 months if you want to confirm response, but expensive and not strictly necessary if your other markers are moving.
For most people taking NR at 300-1000 mg/day, a baseline cardiovascular and metabolic panel before starting and a recheck at 3-6 months covers the relevant ground. Specialty NAD+ testing is optional, the people who actually benefit from it are those running higher chronic doses or wanting to verify response.
Sold as a dietary supplement in most countries. The Niagen form has FDA NDI and GRAS notifications and regulatory clearance in the EU, Canada, Australia, and several other jurisdictions.